



## Syngene appoints Jonathan Hunt as Managing Director and Chief Executive Officer

## Kiran Mazumdar Shaw becomes Non-Executive Chairperson

Bengaluru, 22<sup>nd</sup> January, 2020

The Board of Syngene International Limited has at its meeting held today announced the separation in roles of the Managing Director and Chairperson with effect from April 01, 2020. Accordingly, Mr. Jonathan Hunt, currently Whole-time Director and Chief Executive Officer, will assume the position of Managing Director and Chief Executive Officer of the Company and Ms. Kiran Mazumdar Shaw will become the Non-Executive Chairperson with effect from 1st April 2020.

**Kiran Mazumdar Shaw, Managing Director**, said “Over the past four years, under the leadership of Jonathan Hunt, Syngene has shown considerable growth while expanding its capabilities into new, emerging areas of research and development to meet the existing and future requirements of its clients. His track record demonstrates that he brings strong leadership, an ability to build sustainable partnerships with customers and a clear vision which will drive the Company’s next growth phase.”

**Jonathan Hunt, Chief Executive Officer** commented “It is an honour to be appointed as Managing Director and Chief Executive Officer of Syngene. The company is at the cusp of its next growth phase and I firmly believe that we have the right mix of scientific talent and world class technology, underpinned by a track record of quality and regulatory compliance, to achieve our ambitions. We are continuing to see increasing interest in outsourcing research and development among our customers. Against this backdrop, I believe the opportunities for Syngene are many and I am very pleased to be at the helm for the next phase.”



## About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an innovation-focused global discovery, development and manufacturing organisation providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world. Syngene's clientele includes world leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife. Its innovative culture is driven by the passion of its 4000-strong team of scientists who work with clients from around the world to solve their scientific problems, improve R&D productivity, speed up time to market and lower the cost of innovation. For more details, visit [www.syngeneintl.com](http://www.syngeneintl.com).

## Contact details

Investor Contact	Media Contact
Chanderlekha Nayar P: +91 80 6775 8821 M: +91 72591 92001 Fax: +91 80 2852 3423 E: <a href="mailto:chanderlekha.nayar@syngeneintl.com">chanderlekha.nayar@syngeneintl.com</a>	Sandeep Nair P: +91 80 6775 8775 M: +91 88843 67776 Fax: +91 80 2852 3423 E: <a href="mailto:sandeep.nair@syngeneintl.com">sandeep.nair@syngeneintl.com</a>